English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

This article refers to AspB10 human insulin. Unfortunately, in the title, abbreviations list and two instances on the first page of the article, the misleading term 'insulin aspart B10' was used. The correct title is shown above, and the other sentences are corrected below: Abstract (second sentence): AspB10 human insulin (AspB10), the only insulin analogue with proven carcinogenic activity, has a greater affinity for IGF1R and IR, and a prolonged IR occupancy time. Abbreviations AspB10 AspB10 human insulin Introduction (second paragraph, first sentence) The insulin analogue AspB10 human insulin (AspB10) was withdrawn from clinical development due to a higher incidence of breast cancer in rats [3].

Erratum to: Differences in metabolic and mitogenic signalling of insulin glargine and AspB10 human insulin in rats